Profitability

Miscellaneous

Amgen (NASDAQ:AMGN) Frequently Asked Questions

What is Amgen's stock symbol?

Amgen trades on the NASDAQ under the ticker symbol "AMGN."

How often does Amgen pay dividends? What is the dividend yield for Amgen?

Amgen declared a quarterly dividend on Wednesday, March 7th. Stockholders of record on Thursday, May 17th will be given a dividend of $1.32 per share on Friday, June 8th. This represents a $5.28 dividend on an annualized basis and a dividend yield of 2.96%. The ex-dividend date is Wednesday, May 16th. View Amgen's Dividend History.

How will Amgen's stock buyback program work?

Amgen announced that its Board of Directors has approved a share buyback program on Friday, February 2nd 2018, which allows the company to buyback $10,000,000,000.00 in shares, according to EventVestor. This buyback authorization allows the company to reacquire shares of its stock through open market purchases. Stock buyback programs are generally a sign that the company's leadership believes its shares are undervalued.

How were Amgen's earnings last quarter?

Amgen (NASDAQ:AMGN) posted its earnings results on Tuesday, April, 24th. The medical research company reported $3.47 earnings per share for the quarter, topping the Zacks' consensus estimate of $3.24 by $0.23. The medical research company earned $5.55 billion during the quarter, compared to the consensus estimate of $5.44 billion. Amgen had a return on equity of 35.80% and a net margin of 9.67%. Amgen's revenue was up 1.6% compared to the same quarter last year. During the same period in the prior year, the business posted $3.15 EPS. View Amgen's Earnings History.

When is Amgen's next earnings date?

What guidance has Amgen issued on next quarter's earnings?

Amgen updated its FY18 earnings guidance on Tuesday, April, 24th. The company provided earnings per share guidance of $12.80-13.70 for the period, compared to the Thomson Reuters consensus estimate of $13.47. The company issued revenue guidance of $21.9-22.8 billion, compared to the consensus revenue estimate of $22.71 billion.

What price target have analysts set for AMGN?

22 brokerages have issued 1 year price targets for Amgen's stock. Their predictions range from $161.00 to $220.00. On average, they expect Amgen's stock price to reach $192.1058 in the next year. View Analyst Ratings for Amgen.

What are Wall Street analysts saying about Amgen stock?

Here are some recent quotes from research analysts about Amgen stock:

1. According to Zacks Investment Research, "Amgen’s newer drugs – Prolia, Xgeva, Kyprolis – are performing well. Amgen is also progressing with its pipeline and expects approval and launch of migraine candidate, Aimovig this year. Amgen’s restructuring plan is making it leaner and more cost efficient. Lower taxes and share buybacks should provide some bottom-line support in 2018. Amgen’s shares have outperformed the industry this year so far. However, Amgen has some challenges in store, given slowdown in sales of mature drugs like Enbrel, Aranesp and Neulasta, which are facing an array of branded and generic competitors. Volume growth of new drugs may not be enough to offset the lost sales due to the decline in mature brands. Meanwhile, uptake of key new drug, Repatha has been slow due to payer restrictions. However, estimates have gone up ahead of the Q1 earnings release. Amgen has a positive record of earnings surprises in recent quarters." (4/17/2018)

2. JPMorgan Chase & Co. analysts commented, "AMGN’s top-line continues to be uninspiring, but the bottom line will meaningfully benefit from a lower than expected tax rate (surprise, surprise) and a large, accelerated $10B share buyback. There are several moving pieces to consider heading into 2018 (which are apparent in management’s uncharacteristically wide guidance range), including timing/magnitude of legacy franchise erosion (e.g., Neulasta & Sensipar), trajectory of recent/upcoming launches (e.g., Kyprolis, Repatha, Aimovig), and the extent to which AMGN chooses to exercise its upsized share repurchase authorization (now ~$14B in total). While we continue to be keenly interested in potential for M&A (which AMGN continues to be constructive on) and the earlier stage pipeline, we maintain our Neutral rating pending evidence of sustainable near-/mid-term growth." (2/4/2018)

3. Mizuho analysts commented, "We expect Q4 ’17 trends for both unit demand and net selling price to continue into 2018 – Expect Q1 ’18 sales to be ~ 20% of full year 2018 sales Neulasta US = 969 / 950 / 949 Neulasta Ex-US = 145 / 151 / 152 Neulasta WW = 1114/ 1103 / 1100 Neupogen US = 82 / 87 / 87 PLEASE REFER TO PAGE 5 OF THIS REPORT FOR IMPORTANT DISCLOSURE AND ANALYST CERTIFICATION INFORMATION. Mizuho Securities USA LLC does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision." (2/1/2018)

4. Cann analysts commented, "Amgen yesterday announced that the New England Journal of Medicine (NEJM) published positive results from the six-month phase III STRIVE study evaluating Aimovig (erenumab) versus placebo for the prevention of episodic migraine (between four and 14 migraine days per month). The NEJM article reported that Aimovig delivered clinically meaningful and statistically significant differences from placebo for all primary and secondary endpoints in the study." (11/30/2017)

5. Argus analysts commented, "We would consider a more constructive stance on AMGN on signs of stronger contributions from the company's new drug pipeline or from its biosimilars portfolio," the firm said."We note, however, that Amgen may not generate commercial revenue from biosimilars until 2019 due to regulatory and legal hurdles." (11/1/2017)

Has Amgen been receiving favorable news coverage?

Press coverage about AMGN stock has trended somewhat positive on Thursday, Accern reports. The research group ranks the sentiment of press coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Amgen earned a coverage optimism score of 0.04 on Accern's scale. They also assigned media stories about the medical research company an impact score of 45.89 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near future.

Which major investors are selling Amgen stock?

AMGN stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc., BlackRock Inc., Wells Fargo & Company MN, Northern Trust Corp, Swiss National Bank, The Manufacturers Life Insurance Company , State of Tennessee Treasury Department and Great Lakes Advisors LLC. Company insiders that have sold Amgen company stock in the last year include Carbonnel Francois De, Cynthia M Patton and Sean E Harper. View Insider Buying and Selling for Amgen.

How do I buy shares of Amgen?

Shares of AMGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Amgen's stock price today?

One share of AMGN stock can currently be purchased for approximately $178.38.

How big of a company is Amgen?

Amgen has a market capitalization of $118.02 billion and generates $22.85 billion in revenue each year. The medical research company earns $1.98 billion in net income (profit) each year or $12.58 on an earnings per share basis. Amgen employs 20,800 workers across the globe.

How can I contact Amgen?

Amgen's mailing address is ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA, 91320. The medical research company can be reached via phone at 805-447-1000 or via email at [email protected]

MarketBeat Community Rating for Amgen (AMGN)

MarketBeat's community ratings are surveys of what our community members think about Amgen and other stocks. Vote "Outperform" if you believe AMGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AMGN will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Amgen (NASDAQ:AMGN) Price Target and Consensus Rating

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

22 Wall Street analysts have issued ratings and price targets for Amgen in the last 12 months. Their average twelve-month price target is $192.1058, suggesting that the stock has a possible upside of 7.82%. The high price target for AMGN is $220.00 and the low price target for AMGN is $161.00. There are currently 12 hold ratings and 10 buy ratings for the stock, resulting in a consensus rating of "Hold."

Dividends

Amgen (NASDAQ:AMGN) Dividend Information

Amgen pays an annual dividend of $5.28 per share, with a dividend yield of 2.96%. AMGN's next quarterly dividend payment will be made on Friday, June 8. The company has grown its dividend for the last 7 consecutive years and is increasing its dividend by an average of 23.50% each year. Amgen pays out 41.97% of its earnings out as a dividend.